2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-177972
    Zotadirsen 98%
    Zotadirsen, one of the components of the AOC Delpacibart zotadirsen (HY-177564), is composed of a phosphorodiamidate morpholino oligomers (PMOs) and SMCC linker (HY-42360). Zotadirsen specifically skip exon 44 of the dystrophin gene and enable production of near-full length dystrophin. Zotadirsen can be used to synthesize AOC drugs. Zotadirsen can also be used in the research of Duchenne muscular dystrophy (DM).
    Zotadirsen
  • HY-B0031S
    Quetiapine-d4 fumarate 1287376-15-1 ≥98.0%
    Quetiapine-d4 (fumarate) is the deuterium labeled Quetiapine fumarate. Quetiapine fumarate is a 5-HT receptors agonist and a dopamine receptor antagonist. Antidepressant and anxiolytic effects.
    Quetiapine-d4 fumarate
  • HY-B0124S
    Zonisamide-d4 1020720-04-0 99.38%
    Zonisamide-d4 is the deuterium labeled Zonisamide. Zonisamide (AD 810) is an inhibitor of zinc enzyme carbonic anhydrase (CA), with Kis of 35.2 nM and 20.6 nM for human mitochondrial isozyme hCA II and hCA V, respectively. Zonisamide has antiepileptic activity. Zonisamide can be used for the rsearch for epilepsy, seizures and Parkinson's disease.
    Zonisamide-d4
  • HY-B0184S
    Felbamate-d4 106817-52-1 ≥99.0%
    Felbamate-d4 (W-554-d4) is the deuterium labeled Felbamate. Felbamate (W-554) is a potent anticonvulsant whose clinical effect may be related to the inhibition of N-methyl-D-aspartate (NMDA).
    Felbamate-d4
  • HY-101392S
    Harmane-d1 3013688-52-0 98.01%
    Harmane-d is the deuterium labeled Harmane. Harmane, a β-Carboline alkaloid (BCA), is a potent neurotoxin that causes severe action tremors and psychiatric manifestations. Harmane shows 1000-fold selectivity for I1-Imidazoline receptor (IC50=30 nM) over α2-adrenoceptor (IC50=18 μM). Harmane is also a potent and selective inhibitor of monoamine oxidase (MAO) (IC50s=0.5 and 5 μM for human MAO A/B, respectively).
    Harmane-d1
  • HY-116218C
    Amelparib hydrochloride 98.37%
    Amelparib (JPI-289) hydrochloride is a potent, orally active, and water-soluble inhibitor of PARP-1. Amelparib hydrochloride inhibits PARP-1 activity (IC50 = 18.5 nM) and cellular PAR formation (IC50 = 10.7 nM). Amelparib hydrochloride is a potential neuroprotective agent. Amelparib hydrochloride has the potential for the research of acute ischaemic stroke.
    Amelparib hydrochloride
  • HY-N0168AS1
    (Rac)-Hesperetin-13C,d3 2750534-85-9 99.3%
    (Rac)-Hesperetin-13C,d3 is the 13C- and deuterium labeled (Rac)-Hesperetin. (Rac)-Hesperetin is the racemate of Hesperetin (HY-N0168), an orally active multi-target inhibitor. (Rac)-Hesperetin exhibits significant anti-tumor and anti-inflammatory activities by blocking the TGF-β1-mediated Fyn/RhoA signaling axis and the TLR4-MyD88-NF-κB inflammatory pathway. (Rac)-Hesperetin inhibits the formation of actin stress fibers and the migration and invasion of cancer cells, and is suitable for triple-negative breast cancer research. In inflammation models, (Rac)-Hesperetin effectively alleviates lung injury by reducing the release of pro-inflammatory mediators and regulating the activity of oxidative stress enzymes, and is suitable for acute lung injury research. (Rac)-Hesperetin also interferes with the entry and early replication processes of channel catfish virus, inhibits viral gene expression and progeny virus production, thereby protecting cells from virus-induced cytopathic effects.
    (Rac)-Hesperetin-13C,d3
  • HY-12981
    RG7713 920022-47-5 99.92%
    RG7713 (RO5028442) is a highly potent, selective and brain-penetrant Vasopressin 1a (V1a) receptor antagonist with Kis of 1 nM (hV1a) and 39 nM (mV1a).
    RG7713
  • HY-14198
    Selegiline 14611-51-9 98%
    Selegiline (Deprenyl) is a potent, selective and irreversible inhibitor of MAO-B, with an IC50 of 51 nM. Selegiline exhibits 450-flod selectivity for MAO-B over MAO-A (IC50=23 μM). Selegiline can be used for the research of Parkinson's disease, Alzheimer's disease and major depressive disorder.
    Selegiline
  • HY-14407
    Fosaprepitant 172673-20-0 98%
    Fosaprepitant (L-785298) is a proagent of Aprepitant (HY-10052). Fosaprepitant is a neurokinin-1 receptor antagonist, which is development for the prevention of chemotherapy-induced nausea and vomiting (CINV).
    Fosaprepitant
  • HY-17610
    Enerisant 1152747-82-4 99.79%
    Enerisant (TS-091) is a potent, highly selective, competitive and orally active histamine H3 receptor antagonist/inverse agonist with IC50s of 2.89 nM and 14.5 nM against human and rat histamine H3 receptors, respectively.
    Enerisant
  • HY-B0681
    Acamprosate 77337-76-9 99.34%
    Acamprosate is an orally active prototypic neuromodulator. Acamprosate can be used for the research of alcohol dependence and alcoholism.
    Acamprosate
  • HY-P1013
    Deltorphin 2 122752-16-3 98%
    Deltorphin 2 is a selective peptide agonist for the δ opioid receptor.
    Deltorphin 2
  • HY-100032
    PD 117519 96392-15-3 99.97%
    PD 117519 (CI947) is an A2A adenosine agonist which has shown oral antihypertensive activity in pharmacological animal models.
    PD 117519
  • HY-100728
    BMT-145027 2018282-44-3
    BMT-145027 is an mGluR5 positive allosteric modulator without inherent agonist activity, exhibits an EC50 of 47 nM.
    BMT-145027
  • HY-103089
    LY393558 271780-64-4 99.0%
    LY393558 is a potent and orally active inhibitor of the 5-HT transporter and an antagonist of 5-HT1B and 5-HT1D receptors. LY393558 increase the extracellular levels of 5-HT in mice model frontal cortex. LY393558 can be used for researching depression.
    LY393558
  • HY-107349
    Fenoverine 37561-27-6 99.69%
    Fenoverine (Spasmopriv) is an orally active and powerful anti-spasmodic drug. Fenoverine reduces calcium ion influx by suppressing voltage dependent calcium channels. Fenoverine has antiemetic, analgesic, and antidiarrheal effects. Fenoverine induces rhabdomyolysis. Fenoverine can be used to study smooth muscle overexcitation related conditions such as gastrointestinal spasms.
    Fenoverine
  • HY-110033
    Ecopipam hydrobromide 2587360-22-1 99.0%
    Ecopipam (SCH 39166) hydrobromide is a potent, selective and orally active antagonist of dopamine D1/D5 receptor, with Kis of 1.2 nM and 2.0 nM, respectively. Ecopipam hydrobromide shows more than 40-flod selectivity over D2, D4, 5-HT, and α2a receptor (Ki=0.98, 5.52, 0.08, and 0.73 μM, respectively). Ecopipam hydrobromide can be used for the research of schizophrenia and obesity.
    Ecopipam hydrobromide
  • HY-112612
    RTI-13951-33 2244884-08-8 98%
    RTI-13951-33 is a potent, selective, and brain-penetrant GPR88 agonist, with an EC50 of 25 nM in GPR88 cAMP functional assay. RTI-13951-33 reduces alcohol reinforcement and intake behaviors in rats.
    RTI-13951-33
  • HY-128581
    γ-Secretase modulator 4 1420200-82-3 99.47%
    γ-Secretase modulator 4 is a potent γ-secretase modulator, reduces the Aβ42 level with IC50s of 0.014 μM and 0.017 μM in human and mouse, respectively.
    γ-Secretase modulator 4
Cat. No. Product Name / Synonyms Application Reactivity